EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Can We Diagnose Early Melanoma by Genomics?

W Austin Wyant iD, Dorsa Moslehi, Jennifer A Lo iD

International Journal of Dermatology · 2026

DOI: 10.1111/ijd.70666 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Dermatology, 2026. Verfasst von W Austin Wyant und 2 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Genomics, Early Detection of Cancer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 117 Literaturangaben. Gefördert von: Dermatology Foundation (Dermatologist Investigator Research Fellowship and Physician-Scientist Career Development Award).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma incidence has increased approximately 6‐fold over the past 40 years, driven primarily by melanoma in situ and thin invasive melanomas, which are among the most subjective lesions to diagnose on histopathology. This review examines whether genomics clarifies the “gray zone” between benign and malignant pigmented lesions, or instead recasts existing histopathologic ambiguity in molecular terms, while also considering whether genomic classification shifts overdiagnosis upstream instead of resolving underlying diagnostic uncertainty. Across cytogenetic, mutation‐based, and gene‐expression platforms, current assays perform best in unequivocal melanoma‐versus‐nevus comparisons and lose accuracy in diagnostically ambiguous lesions where clarification is most needed. Gene expression profile (GEP) tests can be useful diagnostic aids in tissue‐rich equivocal lesions, including atypical Spitz tumors, MELTUMPs, and cellular blue nevus/blue nevus‐like melanocytoma differentials. One clinicopathologic‐genomic model, the Merlin CP‐GEP test, has been prospectively validated for predicting sentinel lymph node status and is now recognized as supporting sentinel lymph node biopsy decisions in T1b/T2a melanomas. Importantly, a low‐risk prognostic GEP class assignment should not displace the standard sentinel lymph node biopsy discussion. GEP tests are least useful for small, thin, equivocal junctional proliferations, precisely the lesions that are most difficult to diagnose. Pre‐biopsy non‐invasive assays carry the additional risk of lowering, rather than raising, the biopsy threshold. Overall, current genomic tools should be viewed as an adjunct to, rather than a replacement for, histopathology and clinical context. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsGenomicsEarly Detection of CancerHumansGene Expression ProfilingSentinel Lymph Node BiopsyDiagnosis, DifferentialNevus, Blue

Stichwörter der Autor:innen

dermatologygenomicsmelanoma

Autor:innen und Institutionen

  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

ORCID-Profile: W Austin Wyant, Jennifer A Lo

Förderung

  • Dermatology Foundation (Dermatologist Investigator Research Fellowship and Physician-Scientist Career Development Award)

Zitieren

APA

Wyant, W. A., Moslehi, D., & Lo, J. A. (2026). Can We Diagnose Early Melanoma by Genomics?. International Journal of Dermatology. https://doi.org/10.1111/ijd.70666

Vancouver

Wyant WA, Moslehi D, Lo JA. Can We Diagnose Early Melanoma by Genomics?. International Journal of Dermatology. 2026. doi:10.1111/ijd.70666

BibTeX
@article{Wyant2026,
  author = {Wyant, W Austin and Moslehi, Dorsa and Lo, Jennifer A},
  title = {Can We Diagnose Early Melanoma by Genomics?},
  journal = {International Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ijd.70666}
}
Kostenlos starten →